One thing that is often over looking when valuing SGYP for share price and more importantly
a buyout price is that this. Be certain that Synergy Management is watching very closely how its
first to market competitor, Ironwood is "excepted" as well as every aspect of Ironwood's completion,
sales and response. They can project value, market and acceptance but the one thing that really will
let SGYP Management zero in on a buyout number and real value will be sales and acceptance of the only clear competitor and first to market, Ironwood. Some may think that the first drug out of the blocks has the clear advantage but in this case, I think SGYP has the advantage because since their really are not any alternatives for people at this point then Ironwood and they will try it and sales will be brisk. That said, SGYP will come along with a better, more effective drug will few if any side effects and value will be established, and people will move over to Synergy's drug due to side effects issue (the big D). Woudn' you? I personally dont think we will get to far in this process. Big Pharma is very aware of SGYP and can own it all. They will watch Ironwood's success and that will let them and Synergy truly know SGYP's value. Think about it. When a company is bought, the buyers are either doing a projection on value/sales/market or they look at existing products and calculate what a product in that market might be worth and what they will pay. They can own all of SGYP which is superior drug and best in class. With Ironwood in the $14/share range, I think a buyer may pay anywhere from $20-$30/share for the stock. Synergy Management is smart and has done this before and they want one thing and that is to sell this company early this year for top dollar. Patience will be rewarded.